一分钟看懂
这是一项关于卵巢癌的III 期研究，登记的药物或干预包括Manganese Chloride；Nab-paclitaxel；Platinum chemotherapy；Anti-PD-1 antibody；Placebo，当前状态为招募中。登记地点显示中国北京、唐山、太原有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Manganese Chloride；Nab-paclitaxel；Platinum chemotherapy；Anti-PD-1 antibody；Placebo · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Department of Obstetrics and Gynecology, Seventh Medical Center, Chinese PLA General Hospital · 北京
- Department of Bio-therapeutic, First Medical Center, Chinese PLA General Hospital · 北京
- Department of Obstetrics and Gynecology, First Medical Center, Chinese PLA General Hospital · 北京
- Peking University International Hospital · 北京
- Department of Obstetrics and Gynecology, North China University of Science and Technology Affiliated Hospital · 唐山
- Department of Gynecologic Oncology, Shanxi Province Cancer Hospital · 太原
公开的入选条件
- 1. Patients with histologically or cytologically confirmed epithelial ovarian cancer, primary fallopian tube cancer, or peritoneal cancer.
- 2. Patients who have received at least two prior lines of systemic therapy, including at least one platinum-based regimen.
- 3. Patients who experienced disease progression during or within 6 months after completion of the most recent line of systemic therapy.
- Note: This most recent therapy is not required to be platinum-based and may be any systemic treatment (chemotherapy, targeted therapy, or other anticancer therapy).
- 4. Patients with at least one measurable lesion.
- 5. Patients who have received immunotherapy (anti-PD-1 antibodies, anti-PD-L1 antibodies), or bevacizumab, are not restricted from enrollment.
- 6. Expected survival of more than 6 months.
- 7. Age over 18 years.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07822646；登记信息更新于 2026-09-16。